ÈÕ±¾Åú×¼LEQEMBI?¾²Âö×¢ÉäÒº£¨ÂØ¿¨Ä¹£©ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡

ng28ÄϹ¬ºÍ²³½¡Ðû²¼ £¬ÈËÔ´»¯¿¹¿ÉÈÜÐÔ¾Û¼¯µí·ÛÑùÂѰ×-¦Â (A¦Â)µ¥¿Ë¡¿¹Ìå “LEQEMBI? ¾²Âö×¢Éä£¨ÂØ¿¨Ä¹£º200 mg ¾²Âö×¢ÉäÓÃÒ©ºÍ Leqembi 500 mg ¾²Âö×¢ÉäÓÃÒ©£©ÔÚÈÕ±¾»ñÅú £¬ÓÃÓÚÑÓ»º°¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­£¨MCI£©ºÍÇá¶È³Õ´ôÖ¢µÄ½øÕ¹¡£

LEQEMBIÊÇÒ»ÖÖÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ìå £¬Õë¶Ô¾Û¼¯µÄ¿ÉÈÜÐÔ£¨Ô­ÏËά*£©ºÍ²»¿ÉÈÜÐÔÐÎʽµÄ¦Âµí·ÛÑùÂѰף¨A¦Â£©¡£LEQEMBIÕë¶Ô²¢Çå³ýÁ¬Ðø»ýÀÛµÄ×î¾ßÉñ¾­¶¾ÐÔµÄA¦ÂÐÎʽ £¬²¢Çå³ýÏÖÓÐ°ß¿é £¬ÒÔÖÎÁÆÕâÖÖ½¥½øµÄÂýÐÔ¼²²¡¡£¼Ì 2023 Äê 7 ÔÂÔÚÃÀ¹ú»ñµÃ¹Å°åÅú×¼Ö®ºó £¬ÈÕ±¾Êǵڶþ¸ö»ñµÃÅú×¼µÄ¹ú¼Ò¡£

LEQEMBIµÄ¹Å°åÅú×¼ÊÇ»ùÓÚng28ÄϹ¬µÄ´óÐÍÈ«ÇòClarity ADÁÙ´²ÊÔÑéµÄIIIÆÚÊý¾Ý¡£ÔÚ¸ÃÊÔÑéÖÐ £¬LEQEMBIµÖ´ïÁËÆäÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖÕµãµÄͳ¼ÆÑ§ÒâÒåÉϵĽá¹û £¬²¢Ö¤ÊµÁËLEQEMBIµÄÁÙ´²»ñÒæ¡£Ö÷ÒªÖÕµãÊÇÈ«ÇòÈÏÖªºÍ¹¦Ð§Á¿±í £¬¼´ÁÙ´²³Õ´ôÖ¢ÆÀ·Ö×Ü±í£¨CDR-SB£©¡£Óëο½å¼ÁÏà±È £¬LEQEMBIÖÎÁÆÔÚ18¸öÔÂʱ¼õÉÙÁËCDR-SBµÄÁÙ´²Ï½µ27%¡£±ðµÄ £¬ÓÉAD¿´»¤Õ߯À¹ÀµÄ´ÎÒªÖյ㰢¶û´Äº£Ä¬²¡Ð­×÷Ñо¿×é-Çá¶ÈÈÏÖªÕϰ­-ÈÕ³£Éú»îÄÜÁ¦Á¿±íÆÀ·Ö£¨ADCS MCI-ADL£©ÏÔʾ³ö37%µÄÏÔÖøÍ³¼ÆÑ§»ñÒæ¡£ÕâȨºâµÄÊÇ»¼Õß¶ÀÁ¢ÔË×÷µÄÄÜÁ¦ £¬°üÀ¨Äܹ»´©Ò¡¢Î¹Ê³ºÍ¼ÓÈëÉçÇøÔ˶¯¡£Clarity ADÑо¿µÄÈ«²¿½á¹ûÔÚ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏÐû²¼ £¬²¢Í¬Ê±Ðû²¼ÔÚ2022Äê11ÔÂ29ÈÕµÄͬÐÐÆÀÉóҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£

ng28ÄϹ¬Ê×ϯִÐйÙÄÚÌÙÇç·òÌåÏÖ £¬¡°½ñÌì £¬LEQEMBI »ñµÃÅú×¼ £¬³ÉΪÈÕ±¾Ê׸ö»ñÅúµÄ¿¹µí·ÛÑùÂѰװ¢¶û´Äº£Ä¬²¡ÖÎÁÆÒ©Îï¡£¸ÃÒ©ÎïÔÚ°¢¶û´Äº£Ä¬²¡µÄÔçÆÚºÍÇá¶È³Õ´ô½×¶Î¿É½µµÍ¼²²¡½øÕ¹ËÙ¶È £¬¼õ»ºÈÏÖª¹¦Ð§Ë𺦡£ÎÒÃÇÏàÐÅ £¬ÎÒÃÇÒѾ­ÏÆ¿ªÁ˰¢¶û´Äº£Ä¬²¡ÖÎÁÆÊ·ÉÏеÄÒ»Ò³¡£°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖ½¥½øÐÔµÄÑÏÖØ¼²²¡ £¬²»µ«»á¶Ô»¼Õß¼°Æä»¤Àíͬ°éÔì³ÉÑÏÖØË𺦺͵£¸º £¬»¹»á¶ÔÕû¸öÉç»á±¬·¢¾Þ´óÓ°Ïì £¬×ÔÎÒÃÇÔÚÖþ²¨Ñо¿ÊÒ¿ªÊ¼³Õ´ôÖ¢Ñо¿ÒÔÀ´Ô¼ 40 Äê¼ä £¬ng28ÄϹ¬Ò»Ö±Óë³Õ´ôÖ¢»¼Õß¼°Æä»¤Àíͬ°é¼á³Ö»¥¶¯ £¬²¢Å¬Á¦Á˽âËûÃǵÄÕæÇиÐÊÜ¡£Îª´Ë £¬ÎÒÃDz»¾øÌôÕ½ £¬¿ª·¢Äܹ»´Ó»ù´¡ÉϽâ¾ö°¢¶û´Äº£Ä¬²¡²¡ÀíÎÊÌâµÄÖÎÁÆÒ©Îï¡£ÎÒÃÇÖÂÁ¦ÓÚ½« LEQEMBI ×÷ΪÏû³ý²¡ÒòµÄÐÂÁÆ·¨ £¬ÌṩӦÓÐÐèÒªµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼Õß¼°Æä¼ÒÊô¡£Í¨¹ýÕâЩŬÁ¦ £¬ÎÒÃǵÄÄ¿±êÊǶÔÈÕ±¾Éç»áÖÐÎ§ÈÆ³Õ´ôÖ¢µÄÎÊÌⱬ·¢»ý¼«Ó°Ï씡£

²³½¡×ܲüæÊ×ϯִÐйÙChristopher A. ViehbacherÌåÏÖ£º”»ñµÃÅú×¼ºó £¬ÎÒÃǽ«ÄÜÓëng28ÄϹ¬Ò»Æð×ÊÖú½â¾ö°¢¶û´Äº£Ä¬²¡¶Ô»¼ÕßÔì³ÉµÄÆÆ»µÐÔÓ°Ïì £¬ÒÔ¼°¸ø»¤Àíͬ°é´øÀ´µÄÇé¸Ð¡¢Éç»áºÍ¾­¼Ãµ£¸º¡£ÕâÊDz³½¡ºÍng28ÄϹ¬Îª¿ª´´ÖÎÁÆÕâÖÖÓ°ÏìÊý°ÙÍòÈ˵ļ²²¡µÄÐÂʱ´ú¶øÂõ³öµÄÖØÒªÒ»²½¡£ÎÒÃÇÆÚ´ýÓëng28ÄϹ¬Ð¯ÊÖÏàÖú £¬ÔÚÃÀ¹úºÍÈÕ±¾»ñÅúµÄ»ù´¡ÉÏÔÙ½ÓÔÙÀ÷ £¬ÎªÈ«Çò»¼Õß¼°Æä¼ÒÍ¥´øÀ´ÕâһѡÔñ¡£¡°

ƾ¾ÝºñÉúÀͶ¯Ê¡»®¶¨µÄÅú×¼Ìõ¼þ £¬ÔÚÉÏÊкó»ýÀÛÒ»¶¨ÃüÁ¿µÄ»¼ÕßÊý¾Ý֮ǰ £¬ng28ÄϹ¬½«¶ÔËùÓÐʹÓà LEQEMBI µÄ»¼Õß½øÐÐÉÏÊкóÌØÊâÓÃ;½á¹ûÊӲ죨ȫ²¡Àý¼à²â£©¡£±ðµÄ £¬»¹½«Æ¾¾Ý°üװ˵Ã÷ÊéºÏÀíÍÆ¹ãʹÓà LEQEMBI £¬²¢ÎªÒ½ÁƱ£½¡×¨ÒµÈËÔ±±àдÅàѵÖÊÁÏ £¬ÒÔЭÖúÖÎÀíºÍ¼à²âµí·ÛÑùÂѰ×Ïà¹Ø³ÉÏñÒì³££¨ARIA£©¡£

LEQEMBIµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉng28ÄϹ¬Ö÷µ¼ £¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖÐ £¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£ÔÚÈÕ±¾ £¬ng28ÄϹ¬ºÍ²³½¡ÈÕ±¾½«ÅäºÏÍÆ¹ã LEQEMBI £¬ng28ÄϹ¬½«×÷ΪӪÏúÊÚȨ³ÖÓÐÈË·ÖÏú¸Ã²úÆ·¡£

 

Media Contacts:
Eisai
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com

 

Biogen Inc.
Jack Cox
+ 1 781-464-3260
public.affairs@biogen.com

 

Investor Contacts:?
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122

 

Biogen Inc.
Chuck Triano
+ 1-781-464-2442
IR@biogen.com